DGMT StemCell supplies for E0787301, E0221001 & E0784401
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Points of contact
-
- NCTR Acquisition Liaison nctracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring diagnostic stem cell supplies to support the Public Health and Clinical Excellence (PHCE) project E0787301 and the National Toxicology Program (NTP) project E0221001, with solicitation release estimated for March 1, 2027, and award targeted for May 1, 2027. The procurement covers in-vitro diagnostic substance manufacturing and carries no set-aside restriction.
The estimated award value ranges from $25,000 to $250,000. Interested vendors should direct inquiries to the FDA Acquisition Liaison at nctracquisitions@fda.hhs.gov.
Forecast text
This contract is for medium supplies to support PHCE project E0787301 & NTP project E221001
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast